A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses

Jon M. Steichen(Scripps Research Institute), Ying‐Cing Lin(Ragon Institute of MGH, MIT and Harvard), Colin Havenar‐Daughton(Scripps Research Institute), Simone Pecetta(Ragon Institute of MGH, MIT and Harvard), Gabriel Ozorowski(Scripps Research Institute), Jordan R. Willis(Scripps Research Institute), Laura Toy(Scripps Research Institute), Devin Sok(Scripps Research Institute), Alessia Liguori(Scripps Research Institute), Sven Kratochvil(Ragon Institute of MGH, MIT and Harvard), Jonathan L. Torres(Scripps Research Institute), Oleksandr Kalyuzhniy(Scripps Research Institute), Eleonora Melzi(Ragon Institute of MGH, MIT and Harvard), Daniel W. Kulp(The Wistar Institute), Sebastian Raemisch(Scripps Research Institute), Xiaozhen Hu(Scripps Research Institute), Steffen M. Bernard(Scripps Research Institute), Erik Georgeson(Scripps Research Institute), Nicole Phelps(Scripps Research Institute), Yumiko Adachi(Scripps Research Institute), Michael Kubitz(Scripps Research Institute), Elise Landais(Scripps Research Institute), Jeffrey C. Umotoy(Scripps Research Institute), Amanda M. Robinson(Scripps Research Institute), Bryan Briney(Scripps Research Institute), Ian A. Wilson(Scripps Research Institute), Dennis R. Burton(Scripps Research Institute), Andrew B. Ward(Scripps Research Institute), Shane Crotty(Scripps Research Institute), Facundo D. Batista(Harvard University), William R. Schief(Scripps Research Institute)
Science
October 31, 2019
Cited by 279Open Access
Full Text

Abstract

Vaccine induction of broadly neutralizing antibodies (bnAbs) to HIV remains a major challenge. Germline-targeting immunogens hold promise for initiating the induction of certain bnAb classes; yet for most bnAbs, a strong dependence on antibody heavy chain complementarity-determining region 3 (HCDR3) is a major barrier. Exploiting ultradeep human antibody sequencing data, we identified a diverse set of potential antibody precursors for a bnAb with dominant HCDR3 contacts. We then developed HIV envelope trimer-based immunogens that primed responses from rare bnAb-precursor B cells in a mouse model and bound a range of potential bnAb-precursor human naïve B cells in ex vivo screens. Our repertoire-guided germline-targeting approach provides a framework for priming the induction of many HIV bnAbs and could be applied to most HCDR3-dominant antibodies from other pathogens.


Related Papers

No related papers found

Powered by citation graph analysis